- Ibezapolstat, the first of a novel class of antibiotics, DNA polymerase IIIC inhibitors, is currently commencing a Phase 2b clinical trial in patients with CDI - Using samples from Phase 1 healthy ...

Patients who have cutaneous squamous-cell carcinoma with high-risk features are at risk for recurrence after definitive local therapy. The benefit of systemic adjuvant therapy options has not been ...